Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Sandoz Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: HX575 epoetin alfa (Sandoz)

First Posted Date: 2012-04-12

Last Posted Date: 2017-06-19

Lead Sponsor: Sandoz

Target Recruit Count: 417

Registration Number: NCT01576341

Locations: 🇺🇦
Sandoz Investigative Site, Zhitomyr, Ukraine

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Phase 3

Completed

Conditions: Chemotherapy Associated Neutropenia
Breast Cancer

Interventions: Drug: EP2006
Drug: Filgrastim

First Posted Date: 2012-01-27

Last Posted Date: 2015-05-06

Lead Sponsor: Sandoz

Target Recruit Count: 218

Registration Number: NCT01519700

Locations: 🇨🇿
Insitut Onkologie a Rehabilitaca na Plesi, Ves pod Plesi 110, Czech Republic
🇭🇺
Semmelweis Egyetem, III. Belgyogyaszati Klinika, Budapest, Hungary
🇭🇺
Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Onkoradiologia, Budapest, Hungary

and more 22 locations

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Phase 3

Completed

Conditions: Breast Cancer
Chemotherapy-induced Neutropenia

Interventions: Drug: LA-EP2006
Drug: Neulasta®

First Posted Date: 2012-01-25

Last Posted Date: 2017-08-30

Lead Sponsor: Sandoz

Target Recruit Count: 308

Registration Number: NCT01516736

Locations: 🇪🇸
Sandoz Investigational Site, Valencia, Spain

Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age

Not Applicable

Terminated

Conditions: Short Children Born Small for Gestational Age (SGA)

Interventions: Other: Bloodsampling

First Posted Date: 2011-12-14

Last Posted Date: 2019-08-14

Lead Sponsor: Sandoz

Target Recruit Count: 130

Registration Number: NCT01491854

Locations: 🇷🇴
Novartis Investigative Site, Cluj Napoca, Romania

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Completed

Conditions: Ovarian Cancer
Febrile Neutropenia
Cancer
Prostate Cancer
Lung Cancer
Bladder Cancer
B-cell Lymphoma
Breast Cancer
Multiple Myeloma

First Posted Date: 2011-10-25

Last Posted Date: 2016-01-11

Lead Sponsor: Sandoz

Target Recruit Count: 1496

Registration Number: NCT01459653

Locations: 🇬🇧
Sandoz Investigational Site, Scunthorpe, United Kingdom

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Biological: rituximab
Biological: GP2013

First Posted Date: 2011-08-18

Last Posted Date: 2021-05-14

Lead Sponsor: Sandoz

Target Recruit Count: 629

Registration Number: NCT01419665

Locations: 🇬🇧
Investigative site, Worthing, United Kingdom
🇧🇷
Investigator site, Barretos, Brazil
🇧🇷
Investigative Site, Rio de Janeiro, Brazil

and more 3 locations

Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection

Completed

Conditions: Chronic Kidney Insufficiency

Interventions: Other: In this observational study no study specific intervention is planned

First Posted Date: 2011-05-13

Last Posted Date: 2017-04-07

Lead Sponsor: Sandoz

Target Recruit Count: 102

Registration Number: NCT01353417

Locations: 🇦🇹
General Hospital, Vienna, Austria

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
Drug: Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
Drug: Placebo

First Posted Date: 2011-01-19

Last Posted Date: 2021-02-03

Lead Sponsor: Sandoz

Target Recruit Count: 727

Registration Number: NCT01279057

Locations: 🇺🇸
Sandoz Investigational Site, Waco, Texas, United States

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: MabThera
Biological: GP2013
Biological: Rituxan

First Posted Date: 2011-01-11

Last Posted Date: 2018-01-24

Lead Sponsor: Sandoz

Target Recruit Count: 312

Registration Number: NCT01274182

Locations: 🇺🇸
Miller Clinical Research, Los Angeles, California, United States
🇺🇸
Bluegrass Community Research, Inc., Lexington, Kentucky, United States
🇺🇸
Klein & Associates, Hagerstown, Maryland, United States

and more 17 locations

Clinical Trial With Mesalamine 1g Suppositories

Phase 3

Terminated

Conditions: Proctitis

Interventions: Drug: Mesalamine
Drug: Canasa
Drug: Placebo

First Posted Date: 2010-07-29

Last Posted Date: 2017-03-27

Lead Sponsor: Sandoz

Target Recruit Count: 158

Registration Number: NCT01172444

Locations: 🇮🇳
Kamineni Hospitals, 4-1-1227, King Koti Road, Abids, Hyderabad, Andhra Pradesh, India
🇮🇳
Nizam's Instiute of Medical Sciences, Department of Gastroenterology, Hyderabad, Andhra Pradesh, India
🇮🇳
Andhra Hospitals, Vijayawada, Andhra Pradesh, India

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy